ALGS Aligos Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1799448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY122.2%
TTM net income YoY23.3%
TTM EPS YoY52.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,244.2%
Net margin-1,137.2%
FCF margin—
EBITDA margin-1,223.5%
Returns
ROE-159.5%
ROA-84.5%
ROIC (approx.)-1,147.1%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets76.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio2.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.83M | $0 | $2.83M | $169,000 | $741,000 | $965,000 | $311,000 | $606,000 |
| R&D expense | $18.89M | $24.05M | $23.35M | $17.04M | $23.94M | $13.98M | $14.50M | $16.03M |
| SG&A expense | $5.87M | $5.62M | $6.41M | $4.95M | $5.17M | $5.56M | $5.05M | $5.16M |
| Operating income | -$21.89M | -$1.89M | -$26.93M | -$21.81M | -$28.36M | -$18.57M | -$19.24M | -$20.56M |
| Pretax income | -$21.53M | $1.31M | -$22.72M | -$19.85M | -$31.48M | -$15.68M | $43.13M | -$82.12M |
| Income tax | $326,000 | $2.81M | $317,000 | $30,000 | $56,000 | $185,000 | $43,000 | $27,000 |
| Net income | -$21.86M | -$1.50M | -$23.04M | -$19.88M | -$31.54M | -$15.86M | $43.09M | -$82.15M |
| EBITDA | -$21.59M | -$1.59M | -$26.58M | -$21.56M | -$28.16M | -$18.27M | -$19.05M | -$20.32M |
| EPS (basic) | -2.09 | -0.14 | -2.21 | — | -3.04 | -1.53 | 5.12 | — |
| EPS (diluted) | -2.09 | -0.14 | -2.21 | — | -3.04 | -1.53 | -2.11 | — |
| Weighted avg. shares (diluted) | 10.46M | 10.43M | 10.40M | — | 10.37M | 10.35M | 8.71M | — |
| Banking | ||||||||
| Net interest income | $200,000 | $200,000 | $100,000 | $600,000 | $400,000 | $400,000 | $800,000 | $300,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $31.09M | $30.38M | $29.98M | $18.30M | $42.06M | $18.77M | $73.87M | $37.11M |
| Short-term investments | $0 | $0 | $24.93M | $59.54M | $57.15M | $104.28M | $64.10M | $19.94M |
| Receivables | — | $27.78M | — | — | — | — | — | — |
| Current assets | $34.68M | $62.13M | $59.63M | $82.86M | $103.44M | $127.94M | $143.21M | $62.14M |
| PP&E, net | $1.21M | $1.33M | $1.59M | $1.87M | $2.04M | $2.06M | $2.21M | $2.36M |
| Total assets | $47.19M | $66.33M | $64.56M | $88.53M | $109.76M | $134.71M | $150.70M | $70.09M |
| Current liabilities | $19.60M | $28.34M | $23.32M | $21.23M | $21.99M | $20.27M | $18.95M | $21.74M |
| Total liabilities | $35.88M | $34.44M | $32.77M | $34.99M | $37.93M | $32.84M | $34.25M | $99.07M |
| Shareholders' equity | $11.31M | $31.88M | $31.79M | $53.55M | $71.83M | $101.87M | $116.44M | -$28.97M |
| Shares outstanding | 6.25M | 6.24M | 6.19M | 6.18M | 6.15M | 6.15M | 6.11M | 3.86M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.45M | -$24.95M | -$23.13M | -$21.75M | -$24.34M | -$15.50M | -$20.91M | -$18.40M |
| Investing cash flow | -$127,000 | $25.00M | $34.93M | -$2.02M | $47.68M | -$39.42M | -$44.07M | $19.97M |
| Financing cash flow | -$8,000 | $220,000 | -$62,000 | $123,000 | -$53,000 | -$177,000 | $101.74M | $97,000 |
| Depreciation & amortization | $300,000 | $300,000 | $346,000 | $257,000 | $200,000 | $300,000 | $194,000 | $241,000 |
| Stock-based compensation | $1.28M | $1.36M | $1.31M | $1.46M | $1.47M | $1.16M | $959,000 | $1.71M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.